Ranbaxy

3,437 views

Published on

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,437
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
217
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Ranbaxy

  1. 1. Ranbaxy Laboratories Limited To become a Research based International Pharmaceutical Company Presented By: Aniruddha Nayak Roll- 7 PGDM- II (Since 1961)
  2. 2. Key Drivers of Pharma Growth <ul><li>Significant patent expiries </li></ul><ul><li>through 2011 </li></ul><ul><li>Rationalizing Healthcare costs </li></ul><ul><li>- key priority for Governments </li></ul><ul><li>Increasing genericisation </li></ul>France Spain Italy Russia South Africa India $ Bn Value of Drugs going off patent 2006 - 11 Source : IMS <ul><li>Accelerating branded generics </li></ul>
  3. 3. Key Issues <ul><li>Increasing competition </li></ul><ul><li>Increasing focus on costs </li></ul>
  4. 4. Consolidation - Changing Landscape
  5. 5. The India Pharma Story Source – Financial Times
  6. 6. The Indian Pharmaceutical Industry today is in the front rank of India’s science-based industries . The Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units Several Indian pharmaceutical companies have acquired companies in the US and Europe and many others .
  7. 7. Ranbaxy Today <ul><li>India's largest </li></ul><ul><li>Ranked 8th amongst the global generic pharmaceutical companies </li></ul><ul><li>Ground presence in 49 countries, </li></ul><ul><li>products sold in > 125 </li></ul><ul><li>International business ~ 80% of sales </li></ul><ul><li>Manufacturing locations in 11 countries </li></ul><ul><li>> 11,000 employees, 51 nationalities </li></ul><ul><li>Strong Generics & Innovative research </li></ul><ul><li>capabilities </li></ul>$ 553 $ 972 $ 1339 CAGR 19 % Global Sales Worldwide Presence
  8. 8. <ul><li>For the year 2008, the Company recorded Global Sales of US $ 1,682 Mn, </li></ul><ul><li>R&D has a pool of over 1,200 scientists engaged in research </li></ul><ul><li>Products sold in over 40 countries; manufacturing operations in 6 countries including India </li></ul><ul><li>Employs about 7000 people, 17% of non Indian origin </li></ul><ul><li>Expanding portfolio of international subsidiaries, joint ventures, affiliates and alliances </li></ul>
  9. 10. MISSION:- “To become a research based international pharmaceutical company”. VISION:- Achieving customer satisfaction is fundamental to our business.   Provide product and service of the highest quality. Manage our operation with high concern for strategy and environment.   Be a responsible corporate citizen.
  10. 11. India <ul><li>Fastest growing Company in India </li></ul><ul><li>(Source :ORG-IMS Mat Mar 2007) </li></ul><ul><li>65 new products introduced in 2006 </li></ul><ul><li>Dedicated task forces for Specialized & Chronic therapies </li></ul><ul><li>21 brands in Top 300 of Industry ( 2005 :19) </li></ul>Source : ORG – IMS Audit Nov 2006, Moving Quarter Basis GSK Cipla Ranbaxy 5.0% 4.9% 5.1% Source : IMS - ORG First to market 10 NDDS 6 In-licensed 8
  11. 12. Research & Development New R&D facility for Drug Discovery Research (DDR) R&D I R&D III R&D II R&D IV
  12. 13. Research & Development <ul><li>Dedicated Facilities for Innovative & Generics Research </li></ul><ul><li>> 1400 R&D Personnel ( ~ 250 PhD’s) </li></ul><ul><li>8 - 10 NCE molecules in pipeline </li></ul><ul><li>NDDS based products ( 4 platform technologies) </li></ul><ul><li>R&D collaborations </li></ul>Alliance / Collaboration in DDR Out-licensing in NDDS Out-licensing in DDR
  13. 14. Ranbaxy – GSK Collaboration <ul><li>Expansion of strategic alliance established in 2003 </li></ul><ul><li>Take leads beyond candidate selection to POC* in man </li></ul><ul><li>Therapeutic area focus of AI, Metabolic, Anti-inflammatory </li></ul><ul><li>and Oncology </li></ul><ul><li>> US$ 100 mn in milestone payments and double digit </li></ul><ul><li>royalties on commercialization of a product </li></ul><ul><li>Co- marketing rights in India </li></ul><ul><li>First candidate identified for Respiratory Inflammation </li></ul>Proof of Concept
  14. 15. Major Acquisitions & Alliances <ul><li>Terapia (Romania) </li></ul><ul><li>Be-Tabs (South Africa) </li></ul><ul><li>Allen (Italy) </li></ul><ul><li>Ethimed (Belgium) </li></ul><ul><li>Mundogen (Spain) </li></ul><ul><li>Zenotech (India) </li></ul><ul><li>Krebs (India) </li></ul><ul><li>Jupiter Biosciences *(Ind.) </li></ul><ul><li>Cardinal Drugs (India) </li></ul><ul><li>Auto-injector Tech .(USA) </li></ul>* Subject to due diligence
  15. 16. Niche Alliances <ul><li>Increasing focus on chronic / lifestyle diseases segment </li></ul><ul><li>High entry barriers - technology & resource intensive </li></ul>Fermentation based products Bio-similars & Oncologics Peptides Krebs Zenotech Jupiter* * Subject to due diligence
  16. 17. BRAND RANBAXY OPINION OF DOCTORS TOWARDS RANBAXY PRODUCTS QUALITY
  17. 18. Ranbaxy Brands  •  Analgesics  •  Anti-Peptic Ulcerants    •  Cardiovasculars  •  Cephalosporins    •  CNS  •  Combination Therapy    •  Cough Preparations & Anti-Histamines  •  Dermatologicals    •  Diagnostic Instruments  •  Nutritionals    •  Oral Anti-Diabetics  •  Orthopaedic Segment    •  Other Anti-Infectives  •  Others    •  Quinolones  •  Reagents-Biochemistry    •  Reagents-Cardiac Markers  •  Reagents-HIV/Hepatitis    •  Reagents-Serology  •  Reagents-Torch Range    •  Semi-Synthetic Penicillins    
  18. 20. Repositioning Ranbaxy <ul><li>underwent a sea change during the period 1985-1995 </li></ul><ul><li>diversified into different products, markets and in general over the ‘value curve’ </li></ul><ul><li>tried to create differentiation through Marketing and Process Technology, resulted in improved product/brand profitability, and an increase in brand life cycle </li></ul>
  19. 21. <ul><li>one of the top brands from the Ranbaxy stable that made a successful transition from prescription to OTC markets in India. </li></ul><ul><li>Ranbaxy's Revital successfully shifted from prescription to OTC and became a market leader.  </li></ul><ul><li>“ Jiyo Jee Bhar Ke” </li></ul><ul><li>Yuvraj bats for Ranbaxy’s healthcare brand </li></ul>‘ Revital’ising the brand
  20. 23. In Summary <ul><li>A strong performance on all parameters </li></ul><ul><li>Buoyant performance across key geographies </li></ul><ul><li>Continuing focus on cost optimization </li></ul><ul><li>Robust product flow </li></ul><ul><li>Growth through organic & inorganic </li></ul><ul><li>Discovery pipeline progressing well </li></ul><ul><li>Global Generic rank – 8th </li></ul>
  21. 24. Thank You …

×